Leah Kuntz

Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.

A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.

Posters from Psych Congress confirm the durability of long-term treatment with xanomeline/trospium (Cobenfy).

The CDC just released new data that highlight issues around adult ADHD prevalence, diagnosis, and treatment.

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.

Do you want to be featured in our online series and potentially in print for an upcoming Special Report? Check out our October theme!

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.

DaylightRx becomes the very first FDA-cleared digital treatment for generalized anxiety disorder.

Write to us now to be part of our series on treatment updates this month.